Atrial Fibrillation Global Clinical Trials Review, H2, 2016


#855967

492pages

GlobalData

$ 2500

In Stock

Atrial Fibrillation Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, Atrial Fibrillation Global Clinical Trials Review, H2, 2016" provides an overview of Atrial Fibrillation clinical trials scenario. This report provides top line data relating to the clinical trials on Atrial Fibrillation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Atrial Fibrillation Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Atrial Fibrillation 30
Aug 30, 2016: Trial results for anticoagulants for cardioversion in AF patients published 30
Aug 30, 2016: ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyos Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion 30
Aug 30, 2016: Latest data on dabigatran etexilate safety and effectiveness profile show low rates of bleeding and stroke in NVAF patients in routine clinical care 31
Aug 29, 2016: Real-World Data from Multiple Countries Continue to Reaffirm Positive Benefit-Risk Profile of Bayer's Xarelto in Everyday Clinical Practice 32
Aug 29, 2016: ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care 33
Aug 24, 2016: Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban 34
Aug 24, 2016: Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016 34
Aug 23, 2016: Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 36
Aug 22, 2016: New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayers Xarelto Accepted for Presentation at ESC Congress 2016 37
Clinical Trial Profile Snapshots 40
Appendix 489
Abbreviations 489
Definitions 489
Research Methodology 490
Secondary Research 490
About GlobalData 491
Contact Us 491
Disclaimer 491
Source 492

List of Tables
Atrial Fibrillation Therapeutics, Global, Clinical Trials by Region, 2016* 6
Atrial Fibrillation Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Atrial Fibrillation Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Atrial Fibrillation Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Atrial Fibrillation Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Atrial Fibrillation Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Atrial Fibrillation Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Atrial Fibrillation Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 14
Atrial Fibrillation Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Atrial Fibrillation Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 17
Atrial Fibrillation Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Atrial Fibrillation Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Atrial Fibrillation Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Atrial Fibrillation Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Atrial Fibrillation Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Atrial Fibrillation Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Atrial Fibrillation Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Atrial Fibrillation Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Atrial Fibrillation Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Atrial Fibrillation Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Atrial Fibrillation Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Atrial Fibrillation Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Atrial Fibrillation Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Atrial Fibrillation Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Atrial Fibrillation Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Atrial Fibrillation Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Atrial Fibrillation Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Atrial Fibrillation Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Atrial Fibrillation Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 14
Atrial Fibrillation Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Atrial Fibrillation Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 17
Atrial Fibrillation Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Atrial Fibrillation Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Atrial Fibrillation Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Atrial Fibrillation Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Atrial Fibrillation Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Atrial Fibrillation Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Atrial Fibrillation Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Atrial Fibrillation Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Atrial Fibrillation Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Atrial Fibrillation Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Atrial Fibrillation Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 490